Biogen’s Jean-Paul Kress Joins Syntimmune as President and CEO

Jean-Paul Kress has been appointed president and CEO of Syntimmune. Kress will also serve as a director of the New York-based drug developer. He replaces David de Graaf, who has stepped down as CEO and member of the company’s board of directors. Kress comes to Syntimmune from Cambridge, MA-based Biogen (NASDAQ: [[ticker:BIIB]]), where he was executive vice president and president, international, and head of global therapeutic operations. Syntimmune’s lead compound, SYNT001, is an antibody drug in early-stage clinical trials as a treatment for autoimmune disorders.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.